Correction to: Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy (British Journal of Cancer, (2010), 103, 7, (1019-1024), 10.1038/sj.bjc.6605853);Prognostic role of EGFR gene copy number and KRAS mutation in patients with locally advanced rectal cancer treated with preoperative chemoradiotherapy

British Journal of Cancer

Volumn 103, Issue 7, 2010, Pages 1019-1024

  Bengala, C ^a   Bettelli, S ^a   Bertolini, F ^a   Sartori, G ^a   Fontana, A ^a   Malavasi, N ^a   Depenni, R ^a   Zironi, S ^a   Del Giovane, C ^a   Luppi, G ^a   Conte, P F ^a  

^a UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

EGFR; KRAS; neoadjuvant chemoradiotherapy; rectal cancer

Indexed keywords

BIOLOGICAL MARKER; CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR; FLUOROPYRIMIDINE; FLUOROURACIL; OXALIPLATIN; ANTINEOPLASTIC AGENT; EGFR PROTEIN, HUMAN;

ADULT; AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GRADING; CONTINUOUS INFUSION; CONTROLLED STUDY; COPY NUMBER VARIATION; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; FEMALE; GENE; GENE MUTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KRAS GENE; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PREOPERATIVE RADIOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; RADIATION DOSE; RECTUM CANCER; ADJUVANT THERAPY; ANTAGONISTS AND INHIBITORS; GENE DOSAGE; GENETICS; MIDDLE AGED; MORTALITY; MUTATION; ONCOGENE RAS; PROTO ONCOGENE; RECTAL NEOPLASMS;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DISEASE-FREE SURVIVAL; FEMALE; FLUOROURACIL; GENE DOSAGE; GENES, ERBB-1; GENES, RAS; HUMANS; MALE; MIDDLE AGED; MUTATION; NEOADJUVANT THERAPY; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; RECTAL NEOPLASMS;

EID: 77957232592     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/s41416-024-02790-9     Document Type: Erratum

References (25)

1. Andreyev HJ, Norman AR, Cunningham D, Oates JR, Clarke PA (1998) Kirsten ras mutations in patients with colorectal cancer: the multicenter RASCAL study. J Natl Cancer Inst 90: 675-684 (Pubitemid 28222141)
2. Andreyev HJ, Norman AR, Cunningham D, Oates J, Dix BR, Iacopetta BJ, Young J, Walsh T, Ward R, Hawkins N, Beranek M, Jandik P, Benamouzig R, Jullian E, Laurent-Puig P, Olschwang S, Muller O, Hoffmann I, Rabes HM, Zietz C, Troungos C, Valavanis C, Yuen ST, Ho JW, Croke CT, ODonoghue DP, Giaretti W, Rapallo A, Russo A, Bazan V, Tanaka M, Omura K, Azuma T, Ohkusa T, Fujimori T, Ono Y, Pauly M, Faber C, Glaesener R, de Goeij AF, Arends JW, Andersen SN, Lövig T, Breivik J, Gaudernack G, Clausen OP, De Angelis PD, Meling GI, Rognum TO, Smith R, Goh HS, Font A, Rosell R, Sun XF, Zhang H, Benhattar J, Losi L, Lee JQ, Wang ST, Clarke PA, Bell S, Quirke P, Bubb VJ, Piris J, Cruickshank NR, Morton D, Fox JC, Al-Mulla F, Lees N, Hall CN, Snary D, Wilkinson K, Dillon D, Costa J, Pricolo VE, Finkelstein SD, Thebo JS, Senagore AJ, Halter SA, Wadler S, Malik S, Krtolica K, Urosevic N (2001) Kirsten ras mutations in patients with colorectal cancer: the RASCAL II study. Br J Cancer 85: 692-696 (Pubitemid 32929467)
3. Atkins D, Reiffen KA, Tegtmeier CL, Winther H, Bonato MS, Störkel S (2004) Immunohistochemical detection of EGFR in paraffinembedded tumor tissue: variations in staining intensity due to choice of fixative and storage time of tissue sections. J Histochem Cytochem 52: 893-901 (Pubitemid 38857154)
4. Azria D, Bibeau F, Barbier N, Zouhair A, Lemanski C, Rouanet P, Ychou M, Senesse P, Ozsahin M, Pèlegrin A, Dubois JB, Thèzenas S (2005) Prognostic impact of epidermal growth factor receptor (EGFR) expression on loco-regional recurrence after preoperative radiotherapy in rectal cancer. BMC Cancer 5: 62-71 (Pubitemid 41461069)
5. Bengala C, Bettelli S, Bertolini F, Salvi S, Chiara S, Sonaglio C, Losi L, Bigiani N, Sartori G, Dealis C, Malavasi N, DAmico R, Luppi G, Gatteschi B, Maiorana A, Conte PF (2009) Epidermal growth factor receptor gene copy number, K-ras mutation and pathological response to preoperative cetuximab, 5-FU and radiation therapy in locally advanced rectal cancer. Ann Oncol 20: 469-474
6. Bertolini F, Bengala C, Losi L, Pagano M, Iachetta F, Dealis C, Jovic G, Depenni R, Zironi S, Falchi AM, Luppi G, Conte PF (2007) Prognostic and predictive value of baseline and post treatment molecular marker expression in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Int J Radiat Oncol Biol Phys 68: 1455-1461 (Pubitemid 47176800)
7. Bokemeyer C, Bondarenko I, Makhson A, Hartmann JT, Aparicio J, de Braud F, Donea S, Ludwig H, Schuch G, Stroh C, Loos AH, Zubel A, Koralewski P (2009) Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 27: 663-671
8. Cappuzzo F, Finocchiaro G, Rossi E, Jänne PA, Carnaghi C, Calandri C, Bencardino K, Ligorio C, Ciardiello F, Pressiani T, Destro A, Roncalli M, Crino L, Franklin WA, Santoro A, Varella-Garcia M (2008) EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients. Ann Oncol 19: 717-723 (Pubitemid 351461042)
9. Chung KY, Shia J, Kemeny NE, Shah M, Schwartz GK, Tse A, Hamilton A, Pan D, Schrag D, Schwartz L, Klimstra DS, Fridman D, Kelsen DP, Saltz LB (2005) Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 23: 1803-1810 (Pubitemid 46211358)
10. Dworak O, Keilholz L, Hoffmann A (1997) Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 12: 19-23 (Pubitemid 27138353)
11. Galizia G, Lieto E, Ferraraccio F, De Vita F, Castellano P, Orditura M, Imperatore V, La Mura A, La Manna G, Pinto M, Catalano G, Pignatelli C, Ciardiello F (2006) Prognostic significance of epidermal growth factor receptor expression in colon cancer patients undergoing curative surgery. Ann Surg Oncol 13: 823-835 (Pubitemid 43727367)
12. Gavioli M, Luppi G, Losi L, Bertolini F, Santantonio M, Falchi AM, DAmico R, Conte PF, Natalini G (2005) Incidence and clinical impact of sterilized disease and minimal residual disease after preoperative radiochemotherapy for rectal cancer. Dis Colon Rectum 48: 1851-1857 (Pubitemid 41437667)
13. Giralt J, Eraso A, Armengol M, Rosselló J, Majó J, Ares C, Espin E, Benavente S, de Torres I (2002) Epidermal growth factor receptor is a predictor of tumor response in locally advanced rectal cancer patients treated with preoperative radiotherapy. Int J Radiat Oncol Biol Phys 54: 1460-1465 (Pubitemid 35380048)
14. Giralt J, de las Heras M, Cerezo L, Eraso A, Hermosilla E, Velez D, Lujan J, Espin E, Rosello J, Majó J, Benavente S, Armengol M, de Torres I, Grupo Español de Investigacion Clinica en Oncologia Radioterápica (GICOR) (2005) The expression of epidermal growth factor receptor results in a worse prognosis for patients with rectal cancer treated with preoperative radiotherapy: a multicenter, retrospective analysis. Radiother Oncol 74: 101-108 (Pubitemid 40331866)
15. Iqbal S, Lenz HJ (2001) Determinants of prognosis and response to therapy in colorectal cancer. Curr Oncol Rep 3: 102-108
16. Kim J-S, Kim J-M, Li S, Yoon WH, Song KS, Kim KH, Yeo SG, Nam JS, Cho MJ (2006) Epidermal growth factor receptor as a predictor of tumor downstaging in locally advanced rectal cancer patients treated with preoperative chemoradiotherapy. Int J Radiat Oncol Biol Phys 66: 195-200 (Pubitemid 44175651)
17. Li S, Kim JS, Kim JM, Cho MJ, Yoon WH, Song KS, Yeo SG, Kim JS (2006) Epidermal growth factor receptor as a prognostic factor in locally advanced rectal-cancer patients treated with preoperative chemoradiation. Int J Radiat Oncol Biol Phys 65: 705-712 (Pubitemid 43795832)
18. Moroni M, Veronese S, Benvenuti S, Marrapese G, Sartore-Bianchi A, Di Nicolantonio F, Gambacorta M, Siena S, Bardelli A (2005) Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6: 279-286 (Pubitemid 40590264)
19. Rodel C, Martus P, Papadoupolos T, Füzesi L, Klimpfinger M, Fietkau R, Liersch T, Hohenberger W, Raab R, Sauer R, Wittekind C (2005) Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. J Clin Oncol 23: 8688-8696 (Pubitemid 46211512)
20. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, Dietrich D, Biesmans B, Bodoky G, Barone C, Aranda E, Nordlinger B, Cisar L, Labianca R, Cunningham D, Van Cutsem E, Bosman F (2010) Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol 28: 466-474
21. Shia J, Klimstra DS, Li AR, Qin J, Saltz L, Teruya-Feldstein J, Akram M, Chung KY, Yao D, Paty PB, Gerald W, Chen B (2005) Epidermal growth factor receptor expression and gene amplification in colorectal carcinoma: an immunohistochemical and chromogenic in situ hybridization study. Mod Pathol 18: 1350-1356 (Pubitemid 41348654)
22. Spindler KL, Nielsen JN, Lindebjerg J, Brandslund I, Jakobsen A (2006) Prediction of response to chemoradiotherapy in rectal cancer by a gene polymorphism in the epidermal growth factor receptor promoter region. Int J Radiat Oncol Biol Phys 66: 195-200 (Pubitemid 44332722)
23. Van Cutsem E, Köhne C-H, Hitre E, Zaluski J, Chang Chien CR, Makhson A, DHaens G, Pintér T, Lim R, Bodoky G, Roh JK, Folprecht G, Ruff P, Stroh C, Tejpar S, Schlichting M, Nippgen J, Rougier P (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360: 1408-1417
24. Watanabe T, Wu TT, Catalano PJ, Ueki T, Satriano R, Haller DG, Benson 3rd AB, Hamilton SR (2001) Molecular predictors of survival after adjuvant chemotherapy for colon cancer. N Engl J Med 344: 1196-1206 (Pubitemid 32319494)
25. Zhang W, Park DJ, Lu B, Yang DY, Gordon M, Groshen S, Yun J, Press OA, Vallböhmer D, Rhodes K, Lenz HJ (2005) Epidermal growth factor receptor gene polymorphisms predict pelvic recurrence in patients with rectal cancer treated with chemoradiation. Clin Cancer Res 11: 600-605 (Pubitemid 40116885)